{"id":390489,"date":"2019-01-25T00:00:00","date_gmt":"2019-01-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0044-2019-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/"},"modified":"2026-04-30T23:43:15","modified_gmt":"2026-04-30T23:43:15","slug":"algoim0044-2019-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0044-2019-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/","title":{"rendered":"Crohn&#8217;s Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019"},"content":{"rendered":"<p>Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Children with\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0have a more-complicated disease course compared with adult patients. The primary goal of pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0treatment is to induce and maintain remission as quickly as possible. Historically, treatment of pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s) and then progress to more-potent drugs, such as biologics and\/or immunosuppressants. However, this scenario has largely changed, and physicians increasingly initiate treatment with\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira). The non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0biologics, including Takeda\u2019s Entyvio and Janssen\u2019s Stelara, also have a growing market share.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0patients?<\/li>\n<li>How have Remicade and Humira been integrated into the treatment algorithm?<\/li>\n<li>What proportion of pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with pediatric\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>Real World data<\/strong><\/p>\n<p>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key Drugs Covered<\/strong><\/p>\n<p>Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants<\/p>\n<p><strong>Key Analysis provided<\/strong><\/p>\n<ul>\n<li>Brand\/therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flowcharts<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390489","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390489\/revisions"}],"predecessor-version":[{"id":393613,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390489\/revisions\/393613"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}